Xofluza Approved to Treat, Prevent Influenza in Pediatric Patients
The expanded approval was based on data from two phase 3 studies, miniSTONE-2 and BLOCKSTONE.
Influenza
Influenza A(H3N2) Predominant Strain During 2021 to 2022 Season
Two peaks observed during 2021 to 2022 season, the first in mid-December 2021, the second in mid-March to May 2022
Simultaneous Flu Vaccine, COVID-19 Booster Safe
Systemic reactions generally mild, slightly more likely among those receiving both vaccines compared with COVID-19 mRNA booster alone
NIH Trial Underway for Universal Flu Vaccine
Phase 1 trial testing both intranasal and intramuscular administration
MPR Weekly Dose Podcast #121
Skyrizi gains new approval; the USPSTF make recommendations on multivitamin use to prevent CVD and cancer; an FDA Panel vote on pimavanserin efficacy for treating hallucinations associated with Alzheimer disease psychosis; Phexxi analysed in over 1000 patients; and Vaxneuvance approved for some pediatrics.
CDC Panel Urges Seniors to Get New, More Potent Flu Shot This Fall
Agency urges all Americans aged 6 months and older to get a flu shot every season
FDA Authorizes Direct-to-Consumer Test to Detect COVID-19, Influenza, and RSV
The test is the first non-prescription multi-analyte COVID-19 test that allows individuals to test nasal swab samples self-collected at home.
Interim Estimate Suggests Flu Shot Not Effective in 2021-2022 Season
Vaccine effectiveness against medically attended outpatient acute respiratory infection associated with A(H3N2) was 16 percent
ACIP: 2022 Adult Immunization Schedule Updates
The 2022 adult immunization schedule summarizes ACIP recommendations, including several changes.
Influenza Vaccination Cuts Risk of Critical Illness in Children
During a season predominated by 2 vaccine-mismatched viruses, vaccination was estimated to reduce the risk of life-threatening influenza illness by 75%.
